While APHIS has not approved the use of vaccine to respond to HPAI, the Agency is preparing to ensure that vaccine is available should the decision be made to use it during a future outbreak. Any decision to use vaccination in a future HPAI outbreak would require careful consideration of the efficacy of the vaccine, any impacts of using HPAI vaccine in the field, and the potential trade impacts.
The companies that have been awarded contracts to manufacture avian influenza vaccine for the National Veterinary Stockpile are:
October 13, 2015
HPAI vaccines covered by this award carry either conditional or full licenses from APHIS’ Center for Veterinary Biologics, and were carefully evaluated on a number of factors, including their efficacy against EA H5 viruses. Check this page for information on future RFPs and/or additional contract awards.